...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current opinion in gastroenterology >Recent advances in the treatment of hepatocellular carcinoma
【24h】

Recent advances in the treatment of hepatocellular carcinoma

机译：肝细胞癌治疗的最新进展

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE OF REVIEW: To provide an up-to-date summary of the recent advances in therapies for hepatocellular carcinoma (HCC). RECENT FINDINGS: Surgical resection, liver transplantation, and local ablative therapies such as radiofrequency ablation offer potential cure for tumors detected at an early stage in well selected patients. The role of adjuvant or neoadjuvant therapy is being investigated, but there is no clear evidence supporting its routine use currently. Some have proposed expanding size criteria for transplantation or downstaging tumors detected beyond an early stage, although benefits must be weighed against harms to others on the waiting list. For intermediate-stage HCC, transarterial chemoembolization is the mainstay of treatment, although there is increasing evidence supporting a role for transarterial radioembolization. For advanced HCC, sorafenib is the only systemic therapy to significantly prolong survival in patients with Child A cirrhosis and good performance status. Ongoing trials are evaluating the role of other targeted therapies in patients with advanced HCC. SUMMARY: There have been advances in HCC treatment options over the last couple of years and there are now potential therapies for most patients with any stage of disease. Treatment decisions must be individualized after accounting for factors such as degree of liver dysfunction and patient performance status.
机译：审查目的：提供肝细胞癌（HCC）疗法最近进步的最新概述。最近的发现：外科切除，肝移植和局部消融疗法，如射频消融在精选患者早期检测到的肿瘤的潜在治疗。正在调查佐剂或Neoadjuvant治疗的作用，但目前没有明确的证据证明其常规使用。有些人提出扩大尺寸标准，用于移植或未经早期阶段的移植肿瘤的尺寸标准，尽管必须权衡益处，以防止等待名单上的其他人。对于中期HCC，常规化疗栓塞是治疗的主要阶段，尽管有越来越多的证据证据支持rantarial放射性栓塞的作用。对于先进的HCC而言，索拉非尼是唯一的全身治疗，在肝硬化和良好的性能地位上显着延长了患者的生存。正在进行的试验正在评估其他有针对性疗法在高级HCC患者中的作用。摘要：在过去几年中，HCC治疗方案已经进展，现在大多数疾病患者潜在疗法。治疗决策必须在核算肝功能障碍程度和患者性能状态的因素后进行个性化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号